About us
———
Wuhan Hongren Biopharmaceutical Inc., founded in 2011, is one of the top Chinese CRO providing drug research and development (R&D) services characterized by clinical bioanalysis and non-clinical pharmacokinetic study. The total lab space of Hongren including three sites in Wuhan, Shanghai and Guangzhou exceeds 200,000 ft², with a GLP-compliant bioanalytical platform. Hongren is committed to providing drug R&D services for Pharma & Biotech companies, clinical research centers and drug R&D institutes, to help accelerate the process of drug commercialization.
Project Experiences
1900+

Clinical PK + BE + ADA + PD Studies

1000+

Non-clinical DMPK Studies

140+

On-site inspections organized by CFDI from NMPA and FDA

550+

Provided services for over 500 innovative and generic drugs approved by NMPA

Main Services
—————
Bioanalysis
Data management and statistical analysis
DMPK studies
Non-Clinical Pharmacology Studies
News

Research on Novel Delivery System drug DMPK in New Drug Research and development and its cases Share | Hongren Report of the 14th Academic Conference on Drug and Chemical Foreign Body Metabolism of Chinese Pharmacological Society

Non-clinical and clinical DMPK studies of the new delivery system provide data support for elaborating the characteristics of ADME in vivo. Robust bioanalytical methods are critical. New delivery syst

The application of chemical derivatization technology in biological analysis |

In general, compounds suitable for LC-MS analysis need to have the following characteristics: good chemical stability, easy ionization (ESI, APCI), high abundance, good selectivity of product ions,...

[Big coffee gathers in Wuhan East Lake, bright spots] 132+615 pharmaceutical colleagues talk about the frontier of medicine and seek the future of the industry!

The First Wuhan East Lake Biomedical Innovation and Development Forum, co-sponsored by Hongren Pharmaceutical and Tongji Medical College of Huazhong University of Science and Technology, was successfu

【 Macropharma 】 Structural characterization of ADC drugs and case sharing

Antibody-drug conjugates (ADCs) consist of three main components: Antibodies that selectively recognize antigens on the surface of cancer cells, drug payloads that kill cancer cells, and linkers th...

Common problems and solutions for bioanalysis of polypeptide drugs based on LC-MS detection platform

The biological analysis of polypeptide mainly includes PK pharmacokinetic test, TK pharmacokinetic test and ADA test. The methods used in the analysis mainly include LC-MS/MS and LBA ligand receptor

Key considerations and cases of mesenchymal stem Cell bioanalysis Share | Hongren Pharma Report of the 2nd Greater Bay Area Cell Gene Therapy Development Forum

Biological analysis of stem cells mainly includes: 1, PK and distribution. Among them, clinical distribution detection is difficult due to the limitation of sample sampling. 2. Immunogenicity assessme
—— Contact us ——
【 Contact information 】
Add: Building C1/B4/B6, Optical Valley Biological City, No. 666, Gaoxin Avenue, East East East Lake High-tech Zone, Wuhan
Laboratory Building 2, Zone F, Guoying Industrial Park, No. 666, Shendun Fourth Road, East Lake High-tech Zone, Wuhan
Building 1, Hengyue International Building, Lane 1238, Zhangjiang Road, Pudong, Shanghai
Building C5, Technology Enterprise Accelerator, No.11, Kaiyuan Avenue, Huangpu District, Guangzhou
Postal Code: 430075
【 Service consulting 】
Tel: +86 15997130414 (Ms. Qian) QQ ：2824415271
Mailbox：hongren@hrbiopharm.com
hr-service@hrbiopharm.com